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 Besides lifestyle, various pharmacological treatments have proven their efficacy to prevent type 
2 diabetes in high-risk individuals, especially those with impaired glucose tolerance. Major placebo-
controlled clinical trials demonstrated favourable effects of various glucose-lowering drugs used for the 
treatment of type 2 diabetes, especially metformin, acarbose and thiazolidinediones (glitazones), 
although the distinction between a masking and a true preventing effect is difficult with this type of 
drugs. Because obesity plays a key-role in the pathophysiology of type 2 diabetes anti-obesity agents 
may also be considered as valuable adjunct to diet therapy, especially orlistat, and perhaps sibutramine 
and rimonabant. The effects of lipid-lowering agents, such as statins or fibrates, appear rather modest 
and still controversial in the prevention of type 2 diabetes. In contrast, robust consistent results were 
reported with angiotensin converting enzyme inhibitors and angiotensin AT1 receptor blockers, 
especially in patients with cardiovascular disease including hypertension. In conclusion, besides 
lifestyle intervention that should remain the mainstay for the prevention of type 2 diabetes, many 
pharmacological approaches may offer new options to prevent, or at least delay, the development of 
diabetes in at high risk individuals, and thus to reduce the ongoing epidemics and burden of type 2 
diabetes.  
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 Type 2 diabetes mellitus (T2DM) is associated with excess morbidity and mortality, and is 
considered as one of the most costly and burdensome chronic diseases of our time [1-3]. It is a dynamic 
disease with dual defects, i.e. a progressive insulin secretory defect combined with insulin resistance [4-
6], and is intimately linked to the so-called metabolic syndrome and an increased risk of cardiovascular 
disease [7]. It is well established that the development of T2DM results from an interaction of a 
subject's genetic makeup and their environment [6]. With the increasing prevalence of obesity, the 
prevalence of diabetes is reaching epidemic proportions [3,8]. The development of obesity seems to be 
an important factor portending the development of insulin resistance [9], which in the presence of a 
genetically determined propensity to beta-cell dysfunction results in alterations in glucose tolerance, 
leading to impaired glucose tolerance (IGT), impaired fasting glucose (IFG) and overt T2DM [6,10]. 
Several risk factors have been identified, allowing the screening of so-called high risk individuals 
[11,12]. On the basis of an expert consensus, the American Diabetes Association recommends 
clinicians consider screening for T2DM individuals with such risk factors as family history, 
overweight/obesity, and hypertension [13]. 
 Prevention programmes of T2DM depend on the identification of potentially modifiable risk 
factors [14]. Recently, a great deal of effort has been made on slowing or even preventing the 
development of T2DM in high risk subjects [15,16]. In this context, a life-style intervention, typically 
comprising a combination of diet and exercise, can reduce the risk of progression from IGT to T2DM 
by up to 58% [17,18]. The precise mechanisms by which lifestyle changes reduce the rate of 
development of T2DM in these prevention studies have yet to be reported. However, one can anticipate 
that the resultant weight loss, although rather modest, was associated with improved insulin sensitivity 
[19]. While lifestyle modifications are clearly beneficial in reducing the risk of developing T2DM, they 
cannot be implemented in all clinical settings and are not practical for all subjects [20-22]. In addition 
to lifestyle strategies, various pharmacological approaches have already proven their efficacy in 
preventing or delaying T2DM [23,24]. Therefore, drug therapy targeting either insulin resistance, or 
beta-cell function, or both may be considered to prevent T2DM [25]. Primary prevention may be 
important in the pediatric population because of the rapidly increasing risk in adolescents due to the 
obesity epidemics, although no long-term clinical trial is available in this population yet [26]. Almost 
all antihyperglycaemic agents used for the treatment of T2DM [27] have been assessed or are currently 
evaluated in clinical trials aiming to prevent the development of T2DM in high risk patients : insulin 
secretagogues (sulfonylureas and glinides), metformin, thiazolidinediones (glitazones), acarbose and 




distinguish between a true preventing, a delaying or only a masking effect of diabetes by the 
antihyperglycaemic effect of the drug [30,31]. As obesity plays a crucial role in the pathophysiology of 
T2DM, anti-obesity agents may be considered for the prevention of diabetes in overweight/obese 
patients, especially those with abdominal obesity [9]. Various anti-obesity compounds such as orlistat, 
sibutramine and rimonabant have been or are currently evaluated to prove their efficacy in preventing 
the development of T2DM [28,29]. Because of the complex pathophysiology of T2DM [5,6,10], other 
pharmacological strategies have also been considered. On the one hand, lipotoxicity has been shown to 
promote both insulin resistance and defect in insulin secretion [32]. Therefore, lipid-lowering agents 
may theoretically be used in an attempt to prevent T2DM, although observational data in clinical trials 
with statins and fibrates gave rather disappointing results [28,29]. On the other hand, activation of the 
renin-angiotensin-aldosterone system (RAAS) appears to have deleterious effects on glucose 
metabolism and numerous trials have analyzed the potential beneficial effects of angiotensin-converting 
enzyme (ACE) inhibitors or of angiotensin receptor blockers (ARBs), especially in patients with 
cardiovascular disease [33]. In postmenopausal women, combined therapy with estrogen and progestin 
has also been shown to be associated with a reduction in the incidence of T2DM, despite a negative 
effect on cardiovascular risk [34]. A major objective in the future will be to compare the clinical 
outcomes and cost-effectiveness of all these strategies for managing people at high risk for diabetes, 
especially pharmacological approaches with intensive lifestyle intervention [35]. 
 The aim of the present review article is to describe and discuss the results of clinical trials 
demonstrating a preventive effect of various pharmacological compounds in the development of T2DM 
in at risk individuals. We will successively consider the effects of various glucose-lowering agents, 
anti-obesity drugs, lipid-lowering agents, and inhibitors of the RAAS, to end up with various agents 
(estrogens) and new perspectives (anti-inflammatory compounds). 
 
2. PREVENTION BY GLUCOSE-LOWERING AGENTS (Figure 1) 
 2.1. Metformin 
 Metformin is now considered as the first-line drug for the treatment of T2DM [36] and appears 
to exert several metabolic effects that may be favourable in patients with abdominal obesity and IGT 
[37,38]. Metformin primarily reduces glucose output from the liver, despite no reduction in liver fat 
[39], and could also increase, although to a rather small extend, glucose uptake in the peripheral tissues 
in the presence of insulin, thereby reducing demand on the B cell. Interestingly, favourable effects of 
metformin on body mass index and glucose tolerance have also been observed in obese adolescents 




known to be at high risk to later develop diabetes [40]. A few old studies investigating biguanides 
(metformin) found no significant reduction in the incidence of T2DM compared with placebo using 
intention-to-treat analyses. However, all of these studies had very low diabetes incidence and were 
likely underpowered [28].  
 The largest and most methodologically rigorous trial was the Diabetes Prevention Program 
(DPP) performed in the United States [18]. It randomized 2.155 individuals (age 51 years, BMI 34 
kg/m², 45% high-risk minority groups) with IGT to metformin (850 mg b.i.d.) or placebo (another arm 
assessed the effect of intensive life-style intervention). After a mean follow-up period of 2.8 years, the 
incidence of new diabetes was 7.8% in the placebo-treated patients versus 4.8% in those treated with 
metformin (relative risk [RR] = 0.69, 95% confidence interval [CI] 0.57-0.83). To prevent one case of 
diabetes during a period of three years (number needed to treat or NNT), 14 would have to receive 
metformin. In post hoc subgroup analyses, the benefits of metformin were primarily observed in young 
patients (> 60 years) and in obese patients (BMI > 35 kg/m²). In order to avoid a direct metabolic effect 
of the drug [41], subjects were submitted to a final investigation after a 1-2-week wash-out period. In 
the 79% of eligible patients who completed this last visit, the incidence of diabetes increased from 25.2 
to 30.6% in the metformin group and from 33.4 to 36.7% in the placebo group [42]. When results of the 
washout period were included in the overall analysis, metformin still significantly decreased diabetes 
incidence (RR = 0.75, 95% CI 0.62-0.92). However, as pointed out [31], the washout period was rather 
short (1-2 week only), which could not definitely exclude a partial masking effect [43]. Moreover, 
because type 2 diabetes is a progressive disease [4,5,10] and because the study was rather short (2.8 
years), it remains to demonstrate whether the effect attributed to metformin is really a true preventing 
effect rather than only a delaying effect [30]. Finally, it should be pointed out that the reduction in the 
incidence of T2DM with metformin (31 %) was lower than that obtained with intensive lifestyle 
intervention (58 %) [18].  
 In the Chinese Diabetes Prevention Study, subjects with mild overweight (BMI : 25 kg/m²; 
age : 50 years) and IGT were divided into a control group (n = 85) which received conventional 
education, a metformin group (n = 88 : 250 mg t.i.d.) and an acarbose group (n = 88 : 50 mg t.i.d.) 
(see below 2.4) [44]. Over a 3-year period, 34.9% in the control group versus 12.4% in the 
metformin group progressed to diabetes. This represents an impressive risk reduction of 76.8% for 
metformin, despite the absence of significant weight loss. Unfortunately, the procedure of 
randomization was not described in the paper. 
 The Early Diabetes Intervention Trial (EDIT) was a six-year, prospective, randomised, 




diabetes, and who had two consecutive fasting plasma glucose levels in the range 5.5 to 7.7 
mmol/L. The primary aim of this UK trial was to determine whether deterioration in glucose 
tolerance towards diabetes could be delayed or prevented using a biguanide (metformin, 500 t.i.d.) 
or an alpha-glucosidase inhibitor (acarbose, 50 t.i.d.) (see below 2.4) [45]. The 2 x 2 factorial 
design of this study has the potential to reveal a synergistic effect between metformin and acarbose 
on diabetes prevention. However, the double intervention group is small with just over 160 patients 
and may be underpowered to find such synergy. Six-year results for both arms have been published 
only as abstracts and primary analyses showed no significant difference between groups [45]. Of 
the initial cohort, 31% became diabetic and 14% discontinued follow-up. No differences were seen 
in RR for diabetes by 6 years with metformin (RR = 0.99; p = 0.94) or combination metformin-
acarbose therapy (RR = 1.02; p = 0.91) as compared to placebo. Similarly, non significant 
differences were observed versus placebo in those patients with IGT at baseline. 
 More recently, the Indian Diabetes Prevention Programme (IDPP-1) randomized 531 
individuals with IGT in four groups, control, lifestyle alone, metformin alone (250 mg b.i.d.) and 
combined lifestyle plus metformin. This trial confirmed that lifestyle modification and metformin 
prevent T2DM in Asian Indian subjects with IGT [46]. However, there was no added benefit from 
combining the two approaches after a median follow-up period of 30 months. Of note the average 
dose of metformin was only 250 mg twice daily, thus much lower that that used in the US DPP 
[18]. The 3-year cumulative incidences of diabetes were 55.0% in the control group, 39.3% in the 
group with lifestyle modification, 40.5 % in the group treated with metformin and 39.5% in the 
group given lifestyle advice + metformin. Thus, the relative reduction was 26.4% with metformin 
alone (95% CI 19.1-35.1, p = 0.029), and 28.2 % with combined approach lifestyle plus metformin 
(95% CI 20.3-37.0, p = 0.022). The NNT to prevent one incident case of diabetes was 6.4 for 
lifestyle alone, 6.9 for metformin and 6.5 for lifestyle plus metformin. The absence of synergistic 
effect may be disappointing, especially because the RR reduction of diabetes with lifestyle 
modification was less in the Indian Diabetes Prevention Programme compared with the 58% 
reduction in previous trials, especially the US DPP [18].  In this latter trial, part of the metformin 
effect was attributed to a modest weight loss, which was not observed with metformin in the Indian 
trial, possibly because of the lower daily metformin dose used. 
 Thus, most of the trials performed with metformin gave positive results, despite some 
heterogeneity. As metformin benefits from a long-lasting clinical experience, is generally well-
tolerated and is a rather cheap drug, it should be considered not only as the first choice drug for the 




for the prevention of type 2 diabetes in high-risk individuals, especially those with IGT [35]. 
 
 2.2. Sulphonylureas/glinides 
 While defective insulin secretion has been long considered as a latter event in the natural history 
of T2DM, recent studies have clearly demonstrated that there is an early defect in B-cell function [47], 
even in individuals with IGT [48], especially when insulin secretion is evaluated in comparison with 
insulin resistance [5]. Therefore, the use of insulin secretagogue agents might be considered as a 
potential alternative to prevent progression to T2DM, even if the risk of hypoglycaemia may be a 
serious limitation in clinical practice [49]. As reviewed by Alberti [50], the first-generation compound 
tolbutamide showed positive results in 5 out of 7 intervention trials. However, data interpretation is 
complicated by the fact that these trials preceded the modern definition of IGT and studied "borderline" 
or "chemical" or "latent" diabetes. Two old studies examined the effect of tolbutamide therapy (1000-
1500 mg/day) on diabetes incidence in patients with IGT or high-normal/elevated fasting glucose levels 
[51,52]. Neither study reported a statistically significant decrease in the incidence of T2DM compared 
with control or placebo, although both studies were small (n = 97 and n = 248) and potentially 
underpowered. These negative results were confirmed in a larger and more recent trial (Fasting 
Hyperglycemia Study, reported only in an abstract form) showing that sulphonylurea therapy 
(gliclazide) over six years does not delay progression to diabetes [53]. In this trial, hypoglycaemia was 
a potentially limiting side effect of sulfonylurea therapy, occurring at a frequency of 3% in non-diabetic 
patients. Perhaps an ongoing trial should provide more definitive evidence of the potential interest of 
sulphonylureas. Indeed, the NEPI Antidiabetes Study (NANSY) has recruited almost 2,000 individuals 
with fasting glucose levels of 5.6-6.0 mmol/l, who will be randomized to glimepiride or placebo and 
followed for 5-7 years with diabetes as primary endpoint [54]. 
 Because new insulin-secreting agents of the meglitinide family (repaglinide, nateglinide) have a 
more favourable pharmacokinetic profile that allows to better control postprandial hyperglycaemia 
while reducing the risk of late hypoglycaemia [55], they represent a possible alternative to 
sulphonylurea for the prevention of T2DM. No such demonstration is available yet neither with 
repaglinide nor nateglinide. However, a large trial (NAVIGATOR : "Nateglinide And Valsartan in 
Impaired Glucose Tolerance Outcomes Research") is currently investigating the effect of nateglinide in 
high risk subjects [56]. This multinational, randomised, double-blind, placebo-controlled, forced-
titration, 2 x 2 factorial design trial assessed the effect of nateglinide (30-60 mg t.i.d.) and valsartan (80-
160 mg od) (see below 5.2) on the prevention of diabetes and cardiovascular events in approximately 




progression to diabetes will be evaluated in the core phase of the study (3 years) whereas the prevention 
of cardiovascular events will be evaluated during an extension phase in the same patients. The efficacy 
of nateglinide and valsartan will be determined prospectively using validated measures of diagnosis of 
diabetes, i.e. oral glucose tolerance tests (OGTTs) and/or fasting glucose levels [56]. 
  Thus, the place of insulin secretagogues in the prevention of T2DM is not obvious yet. To this 
respect data from the NAVIGATOR trial are awaited with interest. If positive, i.e. reduced incidence of 
new onset diabetes with a good safety profile, this approach will offer a new alternative for the 
prevention of T2DM in high-risk individuals. New agents capable of stimulating insulin secretion 
and possibly protecting and even regenerating B-cell as well, such as GLP-1 analogues and DDP-
IV inhibitors, offer new exciting perspectives [57]. However, the cost of the new drugs will be 
higher and there are no clinical trials available (or ongoing) demonstrating their interest in the 
prevention of T2DM yet. 
 
 2.3. Glitazones 
 TZDs (glitazones) are insulin-sensitizers with glucose-lowering effects, which are increasingly 
used for the treatment of T2DM [58]. These agents increase insulin sensitivity, both in the peripheral 
tissues (muscle and fat) and liver (reducing hepatic fat depot), thereby decreasing the glucose load on 
the B cell [39]. Besides this classical effect, TZDs may exert beneficial cardiovascular effects and 
protection of B cell, by preserving cell mass and improving insulin secretory function [59,60]. The 
Troglitazone Prevention of Diabetes (TRIPOD) study reported a marked reduction in the incidence of 
T2DM from 45% with placebo to 20% with troglitazone (RR = 0.45, 95% CI 0.25-0.83) in 236 
overweight Hispanic women with previous gestational diabetes (age 35 years, BMI 30.5 kg/m²) [61]. 
This effect was observed after a 2.5 year follow up and occurred despite a modest and nonsignificant 
weight gain of 0.3 kg compared with placebo. However, the nearly 33% attrition rate during follow-up 
is a major limitation of this study. In addition, troglitazone has been withdrawn from the market 
because of liver toxicity [62]. The Pioglitazone In Prevention Of Diabetes (PIPOD) study was 
conducted to evaluate β-cell function, insulin resistance, and the incidence of diabetes during treatment 
with pioglitazone in Hispanic women with prior gestational diabetes who had completed participation 
in the TRIPOD study [63]. Women were offered participation in an open study with pioglitazone (30 
mg/day, uptitrated to 45 mg/day) treatment for 3 three years and 6 months of postdrug washout. 
Metabolic investigation includes both oral and intravenous glucose tolerance tests. The similarity of 
findings between the PIPOD and TRIPOD studies supports a class effect of TZDs to enhance insulin 




with a relatively low rate of T2DM. The lowest rate of diabetes occurred in association with the greatest 
reduction in insulin secretory demands during the first year of treatment. Taken together, findings from 
these two trials support a role for TZDs to modify the natural history of progression to T2DM in high-
risk Hispanic patients. The generalizability to other high-risk groups will require additional studies. 
 In a small cohort study on 172 patients with IGT and insulin resistance, a significant reduction 
in diabetes incidence was observed with thiazolidinedione therapy (troglitazone followed by either 
rosiglitazone 4 mg od or pioglitazone 30 mg od) versus a untreated comparison group after a 3-year 
follow up (RR = 0.11, 95% CI 0.03-0.36) [64]. It was concluded that progression of insulin resistance 
and IGT to T2DM appears to be delayed or prevented with early TZD treatment. 
 In the US Diabetes Prevention Program (DPP), troglitazone (400 mg od) was used initially but 
was discontinued during the trial for safety reason [18]. During the mean 0.9 year (range 0.5-1.5 years) 
of troglitazone treatment, the diabetes incidence rate was 3.0 cases/100 person-years, compared to 12.0, 
6.7, and 5.1 cases/100 person-years in the placebo, metformin and intensive lifestyle participants (p < 
0.001, troglitazone versus placebo and p = 0.02 troglitazone versus metformin) [65]. However, during 
the three years after troglitazone withdrawal, the diabetes incidence rate was almost identical to that in 
the placebo group. It was concluded that troglitazone markedly reduces the incidence of diabetes during 
its limited period of use, but that this action does not persist after drug withdrawal. Whether other 
thiazolidinedione drugs used for longer periods can safely prevent diabetes remains to be determined. 
 The DREAM (“Diabetes Reduction Assessment with ramipril and rosiglitazone 
Medication”) randomised clinical trial evaluated the effect of rosiglitazone (8 mg od) versus 
placebo to prevent T2DM in a large cohort of 5269 individuals with IFG and/or IGT [66]. 
Rosiglitazone (at a maximal daily dose of 8 mg) for 3 years substantially reduced incident T2DM 
(RR = 0.39; 95% CI 0.34-0.45; p < 0.0001) and increased the likelihood of regression to 
normoglycaemia in adults with mild dysglycaemia at baseline (RR = 1.70; 95% CI 1.56-1.86; p < 
0.0001) as compared to placebo. However, as for the first report of the DPP on metformin [18], 
results recently published in the original paper [66] were obtained on treatment with rosiglitazone. 
In the US DPP, part of the prevention effect of metformin disappeared after a short period of 
washout of only 1-2 weeks [42]. Thus, the question whether the remarkable effect obtained with 
rosiglitazone in the DREAM study is a true preventing effect or only a delaying effect or even 
simply a masking effect remains an open question [67]. Data from a previous troglitazone trial 
suggested that the benefit of a TZD persists several months after the drug is stopped [61], although 
this durable effect was not seen in another trial [65]. Therefore, the post-trial washout data of the 




 ACT NOW (“Actos Now for Prevention of Diabetes”) is a smaller ongoing study (n = 600) 
assessing the efficacy of pioglitazone compared to placebo on the prevention of T2DM as primary 
objective in subjects with IGT. The diagnosis is based on 2 OGTTs as recommended [12] and the 
subjects will be treated for approximately 3 years. The results should be available by year 2008.  
 Currently available data suggest that glitazones are the most promising drugs for the prevention 
of T2DM. However, the rather high cost of such pharmacological approach and the possible occurrence 
of adverse effects (weight gain, fluid retention, congestive heart failure) may limit the use of TZDs in 
this indication in the future, especially if high dosage (as in the DREAM trial) is recommended [67]. 
One alternative to increase the efficacy while improving the cost-effectiveness might be to use 
combination pharmacological therapy such as rosiglitazone plus metformin, in addition to a healthy 
lifestyle programme, as currently evaluated in the moderately sized “Canadian Normoglycemia 
Outcomes Evaluation” (CANOE) study in subjects with IGT [68]. 
    
 2.4. Acarbose 
 Antidiabetic drugs of the family of α-glucosidase inhibitors comprise three compounds : 
acarbose, miglitol and voglibose. Their mechanism of action is to retard carbohydrate absorption and 
reduce postprandial glucose responses by inhibiting α-glucosidase enzymes present on the brush border 
of the small intestine which hydrolyze di- and oligosaccharides into their component monosaccharides 
[69]. Of the three α-glucosidase inhibitors, only acarbose has been specifically evaluated in its ability to 
prevent or delay the progression from IGT to T2DM [70]. Acarbose, although almost not absorbed 
from the gut, has been reported to reduce insulin resistance, perhaps through lower postprandial plasma 
glucose concentrations reducing both glucose toxicity and demand on the B cell, and to have the 
potential of preventing diabetes in patients with IGT.  
 The STOP-NIDDM trial is an international multicentre, placebo-controlled study on the 
efficacy of the α-glucosidase inhibitor acarbose in preventing or delaying the development of T2DM in 
a population with IGT [71]. A total of 1,429 subjects (age 55 years, BMI 31 kg/m²) diagnosed with IGT 
and having a fasting plasma glucose concentration > 5.6 mmol/l were randomised in a double-blind 
fashion to receive either acarbose (100 mg t.i.d., n = 714) or placebo (n = 715) for a predictive median 
follow-up period of 3.9 years. The primary outcome is the development of T2DM diagnosed using a 
75-g OGTT. The final analysis of the data regarding primary endpoint showed that 221 (32%) patients 
randomised to acarbose versus 285 (42%) randomised to placebo developed diabetes (RR = 0.75; 95% 
CI 0.63-0.90; p = 0.0015). Despite the small weight loss in the acarbose group probably contributed to 




The results suggest that 11 patients with IGT would need to be treated for 3.3 years to prevent one 
event of development of diabetes. They also suggest that acarbose effectively reduced risk of 
developing T2DM irrespective of age, sex, and BMI. If the diagnosis of diabetes was based on 2 OGTT 
as recommended by the Expert Committee of the American Diabetes Association [12], acarbose 
treatment resulted in a 36.4% reduction in the incidence of diabetes (p = 0.0003). Furthermore, 
acarbose significantly increased reversion of IGT to normal glucose tolerance (p < 0.0001). At the end 
of the study, treatment with placebo for 3 months was associated with an increase in conversion of IGT 
to diabetes, an observation which again suggests that long-term treatment may be mandatory to prevent 
diabetes in such at risk patients. It is noteworthy that almost a quarter of patients discontinued early, of 
whom 48% discontinued during the first year, mostly because of gastrointestinal side-effects. Although 
the molecular mechanisms still need investigation, it was concluded that acarbose could be used, either 
as an alternative or in addition to changes in lifestyle, to delay development of T2DM in patients with 
IGT, especially since the drug has no toxic effects. These conclusions were challenged in a “for debate” 
paper suggesting that the validity of the results of the STOP-NIDDM trial is seriously flawed, because 
of selection bias, inadequate blinding, and bias in data analysis and reporting [72]. However, the 
authors confirmed that the trial results are scientifically sound and credible. The investigators stand 
strongly behind these results demonstrating that acarbose treatment is associated with a delay in the 
development of T2DM (as well as hypertension and cardiovascular complications) in a high-risk 
population with IGT [73]. 
 In the Chinese Diabetes Prevention Study (DPS), subjects with mild overweight (BMI : 25 
kg/m²) and IGT were divided into a control group (n = 85) which received conventional education, 
a metformin group (n = 88) (see above) and an acarbose group (n = 88) [44]. Over a 3-year period, 
34.9% in the control group versus 6.0% in the acarbose group progressed to diabetes. This 
represents an impressive risk reduction of 87.8% for acarbose. However, these remarkable results 
were only partially confirmed in a UK trial, the Early Diabetes Intervention Trial (EDIT) [45]. 
Indeed, primary analyses showed no significant difference in relative risk for T2DM between the 
control group and the acarbose group after a mean 6-year follow-up (RR = 1.04; p = 0.81). 
However, in those patients with IGT at baseline, RR of conversion to T2DM was reduced 
significantly with acarbose (RR = 0.66; p = 0.046) [45]. Even if the number of patients in the 
treatment group was rather small and might be underpowered to show a significant difference, it 
was not smaller, but rather slightly higher, as compared to the Chinese DPS [44]. A already 
mentioned, similar discrepancy between the two trials was observed as far as the effect of 




but may result from the different designs of the two studies, i.e. a randomised controlled trial in 
EDIT versus a cohort study in the Chinese DPS. 
 Thus, acarbose, because of its absence of toxicity and its efficacy to prevent T2DM in 
individuals with IGT in the STOP-NIDDM trial, appears to be a valuable alternative, although not all 
clinical trials provided clear-cut results. In addition, the cost of the drug, although considered as 
acceptable when considering the prevention of both diabetes and cardiovascular events [74], and its 
rather poor gastrointestinal tolerance may represent limitations to use acarbose only for prevention , so 
that the drug should probably considered only for high-risk individuals. 
 
 2.5. Insulin 
 The ORIGIN study is an international randomized placebo-controlled trial examining the 
efficacy of glargine insulin (and/or omega 3 in a 2x2 factorial design) in decreasing the risk of 
cardiovascular events in 12.500 subjects followed for 3.5 years [75]. As a secondary objective, 
investigators will look at the effect of glargine (and/or omega 3) on the development of T2DM whose 
diagnosis will be based on OGTT (however, only 19% of the population have IFG and/or IGT at 
baseline). The results should be available in 2009.  
 
3. PREVENTION BY ANTI-OBESITY AGENTS (Figure 2) 
 Obesity is strongly associated with T2DM [9,19]. Minor long-term changes in body weight 
have beneficial effects on insulin sensitivity and beta-cell function in obese subjects [76], which may 
retard or prevent the progression to T2DM in at risk individuals. Weight loss strategies using dietary, 
physical activity, or behavioural interventions produced significant improvements in weight among 
persons with prediabetes and a significant decrease in T2DM incidence [77]. A recent posthoc analysis 
of the Diabetes Prevention Program revealed that for every kilogram of weight loss, there was a 16 % 
reduction in risk of T2DM, adjusted for changes in diet and physical activity, and concluded that 
interventions to reduce diabetes risk should primarily target weight reduction [78]. However, the rate of 
responders is rather low, the degree of weight loss is generally disappointing and the long-term weight 
maintenance is questionable with life-style changes. Therefore, various anti-obesity drugs have been 
developed in order to improve these outcomes [79,80].    
  
 3.1. Orlistat 
 Orlistat is a gastric and pancreatic lipase inhibitor that blocks the absorption of about one third 




analysis summarizing the results of 29 randomized placebo-controlled studies of orlistat (usual dosage 
of 120 mg t.i.d.), the pooled random-effects estimate of the mean weight loss for orlistat-treated patients 
compared with placebo recipients was 2.89 kg (95% CI, 2.27 to 3.51 kg) after 12 months [80]. The 
placebo-subtracted weight reduction induced by orlistat was even less impressive in adults with type 2 
diabetes (2.0 kg; CI 1.3-2.8) at 12 to 57 weeks follow-up [82]. Despite this modest weight loss, a 
significant reduction in HbA1c levels was consistently reported [82]. This suggests that orlistat may 
enhance insulin sensitivity [83,84], although controversial results have been reported in non-diabetic 
individuals [85]. A pooled analysis of three 2-year randomised clinical trials enrolling 642 obese 
patients reported a non-significant reduction in the incidence of T2DM from 2.0 to 0.6% with orlistat 
therapy (RR = 0.25, 95% CI 0.05-1.2) [86]. The confidence intervals were wide, reflecting the low 
absolute incidence of diabetes within these trials, and attrition rates averaged > 30%.  Nevertheless, 
these observations lead to the concept that orlistat may prevent T2DM in at risk obese patients [87] and 
lead to the initiation of the XENDOS trial.   
  XENDOS (“XENical in the Prevention of Diabetes in Obese Subjects”) is the most important 
RCT performed with orlistat until now, as far as the number of subjects (mean age 43 years, BMI 37.4 
kg/m²) enrolled  (n =3277) and the duration of the trial (4 years) are concerned [88]. It demonstrates 
that the beneficial effects of orlistat on body weight persisted up to 4 years (- 6.9 kg with orlistat 
versus – 4.1 kg with placebo; p < 0.001), although the difference between orlistat and placebo group 
tended to attenuate over time. The most striking finding of XENDOS is that such a modest difference 
in weight reduction (mean of 2.8 kg) was sufficient to significantly reduce the cumulative incidence 
of T2DM (6.2% with orlistat versus 9.0% with placebo; RR = 0.63, 95% CI 0.46-0.86; p = 0.0032). 
The annual incidence of T2DM in XENDOS was 4-5 times lower than in previously mentioned 
trials, mainly because only 21% of enrolled subjects had IGT. The reduction in the incidence of 
T2DM was especially remarkable in those obese patients with IGT at baseline, with a reduction of 
conversion to T2DM after 4 years decreasing from 28.8% in the placebo group to 18.8% in the 
orlistat group (p < 0.005) and a NNT to avoid one event of 11 only. However, the attrition rate was 
57%, partly due to a higher incidence of gastrointestinal side effects with orlistat. XENDOS is the first 
study demonstrating that an antiobesity agent, like orlistat, is able to reduce the progression to 
T2DM in obese subjects as compared with lifestyle changes alone. 
 
 3.2. Sibutramine 
 Sibutramine is a combined norepinephrine and serotonin reuptake inhibitor [89]. At a daily 




(although some thermogenic effects may exist as well) [89]. Weight changes were associated with 
various favourable metabolic effects [90]. A meta-analysis included 44 trials with sibutramine that were 
considered of sufficiently high quality for inclusion in the analysis [91]. Sibutramine was more 
effective than placebo in promoting weight loss in overweight and obese adults at all time points 
assessed, from 8 weeks up to 54 weeks. A Cochrane systematic review included five high-quality 
sibutramine weight loss studies over one year (three weight loss and two weight maintenance trials) 
[79]. Attrition rates averaged 43% during the weight loss phase. Compared to placebo, sibutramine-
treated patients lost 4.3 kg (95% CI : 3.6 to 4.9 kg). The number of patients achieving 10% or greater 
weight loss was 15% (95% CI : 4 to 27%) higher with sibutramine than with placebo. In the STORM 
(“Sibutramine Trial of Obesity Reduction and Maintenance”) study, an individualised management 
programme combining restricted diet and sibutramine achieved weight loss in almost 75% of obese 
patients after 6 months and sustained weight loss in around 50% of patients continuing therapy for 2 
years [92]. A Cochrane review on the use of pharmacotherapy for weight loss in adults with T2DM 
revealed that sibutramine produced significant reductions in body weight (5.1 kg; 95% CI 3.2-7.0) at 12 
to 52 weeks follow-up [82]. However, despite this weight reduction, the average impact on HbA1c was 
rather modest [93], except in patients with the largest weight reduction, possibly because of drug-
associated sympathetic activation [83].  
 There is no direct evidence that sibutramine reduces the incidence of new-onset diabetes in 
overweight/obese patients. A long-term large-scale prospective trial (« Sibutramine Cardiovascular 
and Diabetes Outcome Study » or SCOUT) has been designed to determine whether weight 
management with a novel lifestyle intervention plus either sibutramine (10-15 mg/day) or placebo in 
cardiovascular high-risk overweight and obese patients can impact upon cardiovascular endpoints [94]. 
To be eligible for inclusion, patients must have experienced a cardiovascular event or have diagnosed 
T2DM and another cardiovascular risk factor. The primary endpoint of the trial will include a 
composite cardiovascular endpoint. Because of the size of the study (almost 9,000 patients followed for 
at least 3 years), informative data on the effect of sibutramine on the risk of developing T2DM might 
also be obtained from this trial.  
 
 3.3. Rimonabant 
Rimonabant is the first selective CB1 receptor blocker launched for the treatment of 
overweight/obese subjects with risk factor(s), such as T2DM and dyslipidaemia. The 
endocannabinoid (EC) system, consisting of the cannabinoid type 1 (CB1) receptor and endogenous 




metabolism, both through central orexigenic effects and peripheral metabolic effects in adipose 
tissue, liver, skeletal muscle and pancreas [95,96]. In non-diabetic overweight/obese patients, 
rimonabant 20 mg, as compared to placebo, has been shown to produce significant weight loss and 
waist circumference reduction, the latter being a key marker of intra-abdominal adiposity, and 
improvements in multiple cardiometabolic risk factors. Besides a significant increase in HDL 
cholesterol and a significant decrease in triglyceride levels, improvements in glucose metabolism 
have been described, with a reduction in high fasting insulin levels and HOMA insulin resistance 
index [97-99]. In a 1-year trial performed in overweight/obese patients with diabetes, all these 
effects were confirmed and, in addition, a placebo-subtracted 0.7% reduction in HbA1c levels was 
observed [100]. Almost half of these metabolic effects occur beyond weight loss [101]. Part of these 
metabolic improvements may be attributed to a significant increase in plasma adiponectin levels 
[98]. Rimonabant also improves glucose tolerance and reduces post-glucose load plasma insulin 
response in both RIO-Europe [97] and RIO-Lipids [98]. The favourable effects on plasma glucose and 
insulin levels observed with rimonabant 20 mg after one year persisted after two years in the RIO-
Europe trial [102]. In a pooled post-hoc analysis of the three RCTs performed in non-diabetic patients, 
more obese subjects improved glucose tolerance and fewer individuals progressed towards T2DM in 
the rimonabant 20 mg group as compared to the placebo group [103]. The ongoing RAPSODI 
(“Rimonabant in Pre-Diabetic Subjects to Delay Onset of Type 2 Diabetes”) two-year trial has 
enrolled 2,100 participants, with researchers specifically focusing on whether rimonabant 20 mg 
helps prevent T2DM in patients with pre-diabetes in the form of IFG and/or IGT. 
 
4. PREVENTION BY LIPID-LOWERING AGENTS (Figure 2) 
 There is an intimate relationship between glucose and lipid metabolism [104]. Especially, high 
circulating levels of free fatty acid [105] and ectopic depots of triglycerides in various organs such as 
liver, skeletal muscle, and pancreas [106] have been shown to be associated with increased insulin 
resistance and impaired insulin secretion, leading to the concept of lipotoxicity [33]. Therefore, drugs 
interfering with lipid metabolism may exert favourable effects on glucose metabolism and possibly 
prevent the progression from IGT to T2DM. However, despite some anecdotal small-sized trials, there 
is no convincing and consistent evidence of a favourable effect of statins [107] or fibrates [108,109] on 
insulin sensitivity, and nicotinic acid has been shown to be associated with impaired rather than 
improved insulin sensitivity [110].   
 




 Statins act by inhibiting of HMG-CoA reductase, a key-enzyme in the synthesis of cholesterol 
in the hepatocytes. Besides the remarkable reduction in total and LDL cholesterol levels, they exert 
numerous pleiotropic effects, which may explain their favourable effect of prevention of cardiovascular 
events [111]. Even if they are recognized to improve endothelial function and to reduce low-grade 
inflammation, statins do not exert strong beneficial effects on insulin sensitivity, although some studies 
reported a significant reduction of insulin resistance after statin therapy [107].  In a post hoc analysis 
from the West of Scotland Coronary Prevention Study (WOSCOPS), diabetes incidence was 
significantly lower with pravastatin treatment compared to placebo (1.9% versus 2.8%, RR = 0.70, 95% 
CI 0.50-0.99) [112]. However, the rate of progression to T2DM was low in this trial, leading to a low 
number of events, the prevalence of IGT at entry into the study was unknown and the diagnosis of 
diabetes was only based on self-reporting or a fasting glucose level > 7.0 mmol/l. In three other post 
hoc analyses of large placebo-controlled statin cardiovascular trials, no significant reduction in the 
incidence of new T2DM was observed with the cholesterol-lowering drug : with simvastatin in the 
“Heart Protection Study” (HPS) (4.6% versus 4.0%, 95% CI 1.15, 0.99-1-34) [113], with pravastatin in 
the “Long-Term Intervention with Pravastatin in Ischemic Disease” (LIPID) study (4.0% versus 4.5%, 
0.89, 95% CI 0.70-1.13) [114], and with atorvastatin in the “Anglo-Scandinavian Cardiac Outcomes 
Trial-Lipid Lowerig Arm” (ASCOT-LLA) (3.0% versus 2.6%, RR= 1.15, 95% CI 0.91-1.44) [115]. 
Therefore, there is no current evidence supporting a significant effect of a statin therapy to prevent the 
development of T2DM.  
 A retrospective cohort study using Saskatchewan health databases to identify subjects newly 
started on oral antidiabetic agents from 1991 to 1996 showed that the use of statins is associated with an 
average 10-month delay in starting insulin treatment in 10,996 patients with T2DM initially treated 
with oral antidiabetic agents [116]. However, after 7 years of follow-up, there were no differences 
between the statin and control groups in their requirements for insulin therapy. The Authors asked 
whether this protection also exists for patients at high risk of developing diabetes. A nested case-control 
study based on data from the UK-based General Practice research database concluded that there is little 
if any protective effect of statins on the development of T2DM [117]. 
    
 4.2 Fibrates 
 Because of their specific mechanism of action on PPAR-alpha receptors and their effects on 
circulating triglyceride and free fatty acid levels (FFA), fibrate derivatives may exert more favourable 
effects on glucose metabolism than statins [118]. However, previous studies have yielded conflicting 




were reported to have no effect on insulin resistance. Nevertheless, in  the “Bezafibrate Infarction 
Prevention” (BIP) trial, a post hoc analysis of 303 patients with IGT showed that bezafibrate therapy 
was associated with a significant reduction in T2DM incidence compared with placebo (HR = 0.70, 
95% CI 0.49-0.99) [119]. However, no other trials reported similar favourable results with other 
fibrates, either gemfibrozil or fenofibrate, so that such possible effects of fibrates to avoid progression 
to T2DM require further confirmation. 
 
 4.3. Nicotinic acid 
 Unexpectedly, despite its inhibitory effect on lipolysis and its lowering action on FFA levels, 
nicotinic acid has been shown to be associated with increased insulin resistance rather than improved 
insulin sensitivity. This effect, probably due to a marked rebound in plasma free fatty acid 
concentrations, requires increased insulin secretion to maintain normal glucose tolerance and may lead 
to IGT [110]. Prolonged-release nicotinic acid has improved tolerability as compared to nicotinic acid 
and exerts less deterioration of insulin sensitivity and glucose tolerance, presumably because a less 
marked rebound in plasma FFA levels [120]. Although it may be used in the management of 
dyslipidaemia associated with diabetes and metabolic syndrome [121], there is no evidence that it may 
prevent T2DM in patients with IGT and there is no ongoing trial trying to demonstrate such a protective 
effect. 
 
5. EFFECTS OF RAAS INHIBITION ON DEVELOPMENT OF DIABETES (Figure 2) 
 During recent years, there is a growing interest for the ability to prevent T2DM by the 
inhibition of the RAAS [33,122-124]. It is well known that the risk of new-onset diabetes is increased 
in patients with arterial hypertension. The risk is even greater in patients receiving antihypertensive 
therapy although this may largely vary according to the type of antihypertensive agents used. To this 
respect, old antihypertensive medications such as diuretics and beta-blockers are more deleterious than 
new agents such as calcium channel antagonists and RAAS inhibitors [125-128]. 
  The inhibition of the RAAS has been shown to be associated with various metabolic effects 
that may contribute to protect against the development of T2DM [129]. It resulted in improvement of 
insulin sensitivity in some studies [33,130]. However, the data were heterogeneous across the trials and 
tended to be less consistent with ARBs than with ACE inhibitors. In fact, the effects of ACE inhibition 
on glucose tolerance are more consistent than those on insulin sensitivity. Many reports in non-diabetic 
patients have found some improvement in glucose tolerance, whether assessed by the OGTT or judged 




support for a positive effect of RAAS inhibition on B-cell function and insulin secretion as well 
[131,132]. It remains to be established the extent to which these metabolic effects will influence the 
long-term consequences for future risk of T2DM, especially in at risk populations such as patients with 
arterial hypertension, congestive heart failure or coronary heart disease treated with either ACE 
inhibitors or ARBs [133].  
  
 5.1. ACE inhibitors   
 At least nine trials have examined as a secondary outcome the effect of ACE inhibitors on the 
prevention of T2DM in high risk population [33,122-124]. Most studies were performed in patients 
with arterial hypertension. Except in the STOP-Hypertension-2 study [134] comparing 
enalapril/lisinopril with beta-blocker, a significant reduction in the incidence of new-onset diabetes was 
observed in patients receiving an ACE inhibitor versus patients receiving a comparator, either placebo 
or an active drug (table 2) : “Captopril Prevention Project” (CAPPP) comparing captopril versus 
conventional treatment with beta-blockers or diuretics [135]; “Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial” (ALLHAT) comparing lisinopril versus chlorthalidone or 
lisinopril versus amlodipine [136];  “2nd Australian National Blood Pressure Study” (ANBP2) 
comparing enalapril versus hydrochlorothiazide  [137]; “Anglo-Scandinavian Cardiac Outcomes Trial” 
 (ASCOT) comparing perindopril (added as required to amlodipine) versus atenolol (added as required 
to bendroflumethiazide) [138]. Three studies [139-141] were performed in patients with coronary heart 
disease, with a significant reduction in two out of them [139,140]:  “Prevention of Events with 
Angiotensin Converting Enzyme Inhibition” (PEACE) comparing trandolapril versus placebo [139], 
“International Verapamil-Trandolapril Study” (INVEST) comparing a verapamil sustained 
release/trandolapril (trandolapril as add-on therapy) strategy versus an atenolol/hydrochlorothiazide 
strategy [140], “EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable 
coronary Artery disease” (EUROPA) comparing perindopril with placebo [141]. The “Heart Outcomes 
Prevention Evaluation” (HOPE) trial recruited patients with high cardiovascular risk, because of arterial 
hypertension or the presence of other cardiovascular risk factors and compared ramipril with placebo 
[142,143]. A post-hoc analysis reported a remarkable 35% RRR reduction of new onset T2DM with 
ramipril as compared with placebo at the end of 4.5 year follow up. Interestingly, during a 2.6 year 
extension study, there was a significant further reduction in risk of diabetes for patients in the ramipril 
group versus in the placebo group (RR = 0.66; 95% CI 0.46-0.95) [144]. Thus, the benefits observed 
during the HOPE trial was sustained during passive follow-up despite late similar rates of ACEI use in 




years, there was a 31% RRR in new diagnoses of T2DM in the ramipril group as compared to the 
placebo group. Only one study concerned patients with congestive heart failure. In a retrospective study 
assessing the effect of the ACE inhibitor enalapril on the incidence of diabetes in a small subgroup of 
the "Studies Of Left Ventricular Dysfunction" (SOLVD) [145], a dramatic reduction of new cases of 
T2DM was noticed in patients treated with enalapril as compared to those receiving placebo. By 
multivariate analysis, enalapril was the most powerful predictor for risk reduction of developing T2DM 
(RR = 0.22; 95 % CI 0.10 to 0.46; p < 0.0001). Despite this almost remarkable consistency of the 
observations, it should be pointed out, however, that all these results were the product of a post hoc 
analysis or the secondary results of trials projected for a different scope, i.e. cardiovascular protection, 
and obtained using heterogeneous criteria for diabetes diagnosis. Unfortunately, the prevalence of IGT 
is unknown in those study populations. Thus, the consistent positive findings that ACE inhibitors may 
prevent T2DM should receive a definite answer after completion of large-scale trials specifically 
devoted to answer this important question. 
  As already mentioned, the DREAM ("Diabetes REduction Approaches with ramipril and 
rosiglitazone Medications") trial was designed to evaluate prospectively whether ramipril 15 mg od 
prevents T2DM among individuals at high risk because of IGT or IFG [146]. After a median follow-up 
of 3 years in 5269 participants, the incidence of the primary outcome (effects of ramipril on the 
development of T2DM or death) did not differ significantly between the ramipril group (18.1%) and the 
placebo group (19.5%; HR = 0.91; 95% CI 0.81-1.03; p =0.15). However, participants receiving 
ramipril were more likely to have regression to normoglycaemia (a prespecified secondary outcome) 
than those receiving placebo (HR = 1.16, 95% CI 1.07-1.27; p = 0.001). Thus, among persons with IGT 
or IFG, the use of ramipril for 3 years does not significantly reduce the incidence of T2DM or death but 
does significantly increase regression to normoglycaemia. There may be several reasons why the results 
of DREAM differ from the reductions in the rates of newly diagnosed diabetes reported previously with 
ACE inhibitors. Besides the use of a more rigorous protocol concerning the definition of diabetes and 
its screening at baseline and during the study, it is of note that participants of DREAM differed from 
those of previous studies, who were older and primarily had known cardiovascular disease, heart 
failure, hypertension, or a combination thereof. It is possible that the degree of activation of the RAAS 
is higher in the latter patients and that the ACE inhibition may therefore have a greater effect in these 
people than in others as those recruited in DREAM. Thus, ACE inhibitors are not recommended to 
prevent T2DM in absence of other cardiovascular risk factors [147]. Nevertheless, the results of 
DREAM suggest that ramipril may have favourable effects on glucose metabolism (mild reduction in 




other reports on studies of ACE inhibitors. 
 
 5.2. Angiotensin receptor blockers 
 At least four studies assessed the efficacy of an ARB and three out of them demonstrated a 
significant reduction in new cases of T2DM in hypertensive patients as compared to a placebo or an 
other active antihypertensive drug [33,122-124] : “Losartan Intervention For Endpoint reduction in 
hypertension study” (LIFE) comparing losartan with atenolol [148,149]; “Antihypertensive treatment 
and Lipid Profile In a North of Sweden Efficacy Evaluation” (ALPINE) comparing candesartan with 
hydrochlorothiazide [150]; “Valsartan Amlodipine Long-Term Use Evaluation” (VALUE) comparing 
valsartan and amlodipine [151]. Only the “Study on Cognition and Prognosis in the Elderly” (SCOPE) 
comparing candesartan versus placebo showed a 25% difference that did not reach statistical 
significance [152]. These observations in hypertensive individuals were confirmed in one trial in 
patients with congestive heart failure, the “Candesartan in Heart failure Assessment of Reduction in 
Mortality and morbidity” (CHARM) study [153,154].  After a mean follow-up of 37.7 months, the 
number of newly diagnosed patients as having diabetes was significantly lower with candesartan (6%) 
than with placebo (7%) : HR = 0.78; 95% CI, 0.64-0.96; p = 0.020. There is therefore enough 
circumstantial evidence to justify a prospective study on the effect of ARB on the prevention of T2DM 
in high risk population. 
 The NAVIGATOR ("Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes 
Research") is an international randomized placebo-controlled 2x2 factorial design to assess the effect of 
nateglinide (see above 2.2) and/or valsartan on the prevention of T2DM and cardiovascular events as 
primary outcomes in subjects with IGT and high risk for cardiovascular disease [56]. The diagnosis of 
diabetes is based on the OGTT. More than 9,500 individuals were recruited and will be followed for 3 
years. The results should be available in 2007. ONTARGET (“Telmisartan Alone and in combination 
with Ramipril Global Endpoint trial”) is a three-arm study testing telmisartan, ramipril and telmisartan 
plus ramipril on cardiovascular events in a high risk population of 22,440 subjects [155]. Those 
individuals who cannot tolerate ACE inhibitors will be enrolled in a parallel study, TRANSCEND 
(“Telmisartan RANdomized assessment Study in angiotensin inhibitor intolerant patients with 
cardiovascular Disease”) which will compare telmisartan with placebo in almost 5,000 individuals. The 
ONTARGET-TRANSCEND studies will also look at the effect of those treatments on the development 
of T2DM based on fasting plasma glucose as a prespecified secondary outcome. ONTARGET will also 
offer the unique opportunity to compare the effects of an ACE inhibitor and an ARB in a head-to-head 




prevent T2DM as compared to monotherapy. The use of telmisartan is also of special interest as this 
highly lipophilic ARB has been shown to exert partial PPAR-γ activity (selective PPAR modulator or 
SPPARM), thus an effect related to glitazones, which may bring an add-on value for the prevention of 
T2DM [156,157]. The results should be available in 2007-2008, after a mean follow-up of 5.5 years. 
 
 In conclusion, there is growing and consistent evidence that RAAS inhibition may prevent the 
development of T2DM in high-risk individuals. Indirect comparison suggests that ACE inhibitors and 
ARBs have a similar and significant ability to reduce the occurrence of new-onset T2DM among 
subjects with arterial hypertension, congestive heart failure and coronary heart disease [33, 122-124, 
133]. Therefore, an ACE inhibitor or ARB is a logical first-line antihypertensive therapy in patients 
with IFG or metabolic syndrome for multiple reasons, including the reduction of risk of progression to 
overt T2DM. Obviously, part of the antidiabetic mechanisms occurs beyond the RAAS [158]. 
However, as shown recently by the results of DREAM, the routine use of ACE inhibitor such as 
ramipril for the express purpose of preventing diabetes, in absence of cardiovascular disease, is not 
indicated. 
  
6. PREVENTION BY VARIOUS DRUGS (Figure 2) 
 6.1. Estrogen 
 There is increasing evidence both in rodents and in humans linking the endogenous estrogen 
17β-estradiol (E2) to the maintenance of glucose homeostasis [159,160]. Five cohort studies, which 
have examined the association between estrogen use and T2DM incidence, reported controversial 
results [28]. However, several trials failed to adjust for potentially important covariates such as family 
history of T2DM, body weight, or baseline glucose measurements. The Nurses Health Study, the 
largest of the cohort studies, found that over 12 years, current estrogen use was associated with a 
significant reduction in T2DM incidence compared with never users, but no difference between former 
estrogen users and never users [161] (Table 4). In the Strong Heart Study in American Indian 
postmenopausal women, the risk of T2DM was not significantly increased when comparing current 
users versus past or never users, but increased modestly with increasing duration of estrogen use 
among current users, with an odds ratio of 1.10 per year of use [162].  In contrast, a recent study 
revealed that transdermal 17-β-estradiol significantly reduced the risk of developing T2DM in 
healthy, nonobese, postmenopausal [163] (Table 4). 
 The two most important data result from post hoc analysis of the HERS (“Heart and 




studies [165,166]. In HERS, combination estrogen and progesterone therapy was associated with a 
significant reduction in the incidence of T2DM from 9.0 to 6.2% compared with placebo (RR = 0.65) 
[164]. In the WHI Trial, the cumulative incidence of treated diabetes after 5.6 years of follow-up was 
3.5% in the hormone therapy group (daily 0.625 mg conjugated equine oestrogens plus 2.5 mg 
medroxyprogesterone acetate) and 4.2% in the placebo group (HR = 0.79) [165]. However, there was 
little change in the HR after adjustment for changes in BMI and waist circumference. During the first 
year of follow-up, changes in fasting and insulin levels indicated a significant fall in insulin resistance 
in actively treated women compared with the control group. In a substudy of this large trial, the effect 
of daily 0.625 mg conjugated equine oestrogen alone were compared to placebo in women who had 
previously had a hysterectomy [166]. After a mean 7.1-year follow-up, the cumulative incidence of 
treated T2DM was 8.3% in the oestrogen-alone group and 9.3% in the placebo group (HR 0.88, p = 
0.072) (Table 4). A significant reduction in insulin resistance assessed by the HOMA-model was 
observed after 1 year, but not after 3 and 6 years of follow-up. Therefore, the effect appears to be 
smaller with oestrogen alone than that seen with oestrogen plus progestin.   
 These recent data suggest that combined therapy with estrogen and progestin reduces the 
incidence of T2DM, possibly by a decrease in insulin resistance unrelated to body size. However, in 
view of the overall adverse effects of this combination, especially the increased risk of cardiovascular 
disease, it is not justified to use combined estrogen plus progestin therapy for the prevention of T2DM 
in postmenopausal women. Nevertheless, further study of mechanisms seems warranted to explore the 
role of hormonal factors in diabetes prevention. Recent data from the Rancho Bernardo Study showed 
that proinsulin, but not insulin, levels were significantly lower in current hormone replacement therapy 
users than in previous and never hormone replacement therapy users [167]. Proinsulin reflects insulin 
resistance more than intact insulin and hyperproinsulinaemia may be a sign of a pancreatic B-cell 
defect, augmented by an increased demand placed on the B cell. The effects of estrogen on insulin 
secretion merit further investigation and might lead to new therapies [168]. Further studies of 
alternative postmenopausal hormone therapy regimens and selective estrogen agonists and/or 
antagonists should consider the effects of these regimens on insulin resistance, insulin secretion and 
new-onset T2DM. 
  
 6.2. Anti-inflammatory drugs 
 There is a growing body of evidence for the role of inflammation in insulin resistance and 
T2DM [169-171]. More than 15 studies in different ethnic groups have shown a remarkable 




some other inflammatory markers predict the development of T2DM [172-176]. For example, an 
overall inflammation score based on four inflammatory markers plus white cell count and fibrinogen 
predicted diabetes in the Atherosclerosis Risk in Communities Study participants [177]. In general, the 
predictive power of hs-CRP, the most widely used marker, was somewhat stronger than that of Il-6. 
However, it was reduced after adjustment for BMI or other factors related to insulin resistance, 
although it remained a significant independent risk marker in most studies. In addition, almost 10 
prospective studies have demonstrated that low adiponectin levels predict an increased incidence of 
T2DM [178]. For instance, in the Atherosclerosis Risk in Communities Study, a case-cohort study 
representing the approximately 9-year experience of 10,275 middle-aged US participants, hazard ratios 
(95% CIs) for developing T2DM, for those in the second, third and fourth (versus the first) quartile of 
adiponectin were 0.72 (0.48-1.09), 0.67 (0.43-1.04) and 0.58 (0.34-0.99), respectively, after extensive 
adjustments for all known confounding risk factors [179]. Thus, there is accumulating evidence 
suggesting that inflammation is the bridging link between obesity, T2DM and atherosclerosis. Thus, 
interventions using agents with anti-inflammatory properties may reduce the risk of both conditions. 
 Evidence is emerging that many drugs that may reduce the incidence and/or delay the onset of 
T2DM have apparent “anti-inflammatory” properties [180]. It is the case for thiazolidinediones, 
metformin, ACE inhibitors, ARBs, fibrates and statins, which all are able to reduce hs-CRP levels and 
other inflammatory markers [181]. However, although all these drugs with potential anti-inflammatory 
properties reduce the risk of developing T2DM, it is difficult to prove whether such anti-inflammatory 
properties contribute to their diabetes prevention effect and, if yes, to what extent. Indeed, nearly all 
drugs have other, often more pronounced, metabolic actions that can explain the prevention effect of 
T2DM. Thus, only specific trials wit drugs exerting specific anti-inflammatory effects may answer the 
question. High-dose aspirin inhibits cyclooxygenase and IkappaB kinase-beta and reduces fasting 
plasma glucose concentration in patients with T2DM [182]. While controversial results about the effect 
of acetylsalicylic acid on insulin resistance have been reported, a recent study in healthy men showed 
that acetylsalicylic acid specifically attenuates the lipid-induced insulin resistance, but not insulin 
resistance in absence of high lipid levels [183]. However, this beneficial effect of ASA was not 
accompanied by any changes in inflammatory markers. Unfortunately, there has not, as yet, been a 
large-scale trial to examine the effect of aspirin on the risk of developing T2DM. Clinical trials to test 
efficacy, tolerability, and durability of salsalate (nonacetylated salicylate) are currently being 
undertaken in the NIH-funded TINSAL-T2DM and cardiovascular trials (Targeting Inflammation with 
Salsalate in T2DM and cardiovascular disease, respectively). Other more specific anti-inflammatory 




are being considered, but these studies are at much earlier stages [171]. Studies with these novel 
inhibitors of inflammatory pathways will help determine whether targeting the inflammation axis is a 
fertile mechanism to prevent (or treat) T2DM [181].  
  
6. CONCLUSION  
 The goal of ultimately reducing the population burden of diabetes by early treatment and 
prevention is clearly of pivotal importance. Obviously, intensive lifestyle intervention is the 
mainstay for the prevention of T2DM given the remarkable reduction in the incidence of T2DM, 
the prolonged benefits, the demonstrable cost effectiveness and the absence of adverse events. 
Unfortunately, intensive lifestyle intervention is difficult to implement and to sustain in most 
individuals and many subjects will still progress to T2DM. Besides life-style modifications, 
pharmacological strategies using various glucose-lowering agents, antiobesity drugs and 
compounds that inhibit RAAS activity might be considered as a valuable alternative. Owing to the 
pathophysiology of T2DM, these drugs must act either by reducing insulin resistance and/or by 
improving insulin secretion, with a special interest in the protection of beta cells. The effects of 
lipid-lowering agents are more controversial so that these compounds should be used for their 
cardiovascular protection but not for diabetes prevention. Although estrogen use is controversial as 
far as cardiovascular prevention is concerned, increasing evidence suggests that estrogen may 
prevent T2DM in post-menopausal women. As chronic inflammation seems to play a role in the 
pathophysiology of T2DM, it is plausible that new compounds will emerge in a near future 
targeting this abnormality. As far as glucose-lowering agents are concerned, an at least partial masking 
effect should be excluded because most results were obtained either when subjects were still on the 
drug or after a rather short washout period. In addition, because T2DM is a progressive disease, it 
remains to be established in long-term studies whether the so-called preventing effect is not simply a 
postponing effect.  
 It is of note that no pharmacological agent is currently approved for the particular indication of 
diabetes prevention. However, because so many different pharmacological approaches may be 
theoretically used, a practical key question would be which one should be chosen for each patient. 
Besides the phenotype of the patient, it is expected that genotype studies will help in the selection in a 
near future. Another interesting question is whether combined drug therapy may add further protection 
against new-onset diabetes. Although no additive protection was observed in the DREAM study with 
the rosiglitazone-ramipril combination as compared to rosiglitazone alone, new ongoing trials assessing 




telmisartan + ramipril) would provide partial answer to this last question. Finally, all available data and 
ongoing trials are limited to the middle-aged or elderly population. The prevalence of diabetes is 
growing rapidly in adolescents so that preventive measures, including pharmacological approaches 
when necessary, should be implemented rapidly among paediatric patients and presumable should 
target first overweight/obese young people with a family history of T2DM. However, long-term 
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Figure 1 : Illustration of the sites of action of oral glucose-lowering agents used in the various clinical 
trials of prevention of type 2 diabetes in high risk patients (mainly because of impaired glucose 
tolerance) 
 
Figure 2 : Various hypothetical mechanisms implicated in the pathogenesis of type 2 diabetes and 
illustration of the sites of action of non-glucose-lowering agents considered for the prevention 





Table 1 : Placebo-controlled randomised clinical trials assessing the effect of metformin, acarbose, and 
thiazolidinediones on the incidence of new-onset diabetes in patients with impaired glucose tolerance. F-
U : follow-up. RR : relative risk of developing diabetes versus placebo. 95% CI :95% confidence 
interval. NA : not available 
 
Trial [Reference] Drug  Daily dose F-U n RR (95% CI)  p 
         mg  years 
 
US DPP [18]  Metformin 850 mg b.i.d. 2.8 2155 0.69 (0.57-0.83)  0.001 
CDPS [44]  Metformin 250 mg t.i.d. 3 261 0.23 (NA)  0.0002  
EDIT [45]  Metformin 500 mg t.i.d. 6 631 0.99 (NA)  0.94 
Indian DPP [46]  Metformin 250 mg b.i.d. 2.5 531 0.74 (0.65-0.81)  0.029  
 
TRIPOD [61]  Troglitazone 400 mg o.d. 2.5 236 0.45 (0.25-0.83)  0.01 
US DPP [65]  Troglitazone 400 mg o.d. 0.9 585 0.25 (NA)  0.02 
DREAM [66]  Rosiglitazone 8 mg o.d. 3.0 5269 0.40 (0.35-0.46)  0.0001 
 
STOP-NIDDM [71] Acarbose 100 mg t.i.d. 3.2 1368 0.75 (0.63-0.90)  0.0015 
CDPS [44]  Acarbose 50 mg t.i.d. 3 261 0.12 (NA)  0.00001 
EDIT [45]  Acarbose 50 mg t.i.d. 6 631 1.04 (NA)  0.81 
   Acarbose  50 mg t.i.d. 6 ? (*) 0.66 (NA)  0.046 
 
 





Table 2 : Randomised clinical trials assessing the effect of ACE inhibitors (ACEI) on the incidence of 
diabetes in high-risk patients with hypertension, congestive heart failure and coronary artery 
disease. In the bottom, results of the DREAM study performed in patients without high 
cardiovascular risk. F-U : follow-up. RR : relative risk of developing diabetes versus 
comparator. 95% CI : 95% confidence interval. HCTZ : hydrochlorothiazide. NA = not 
available. NS : not significant. 
 
Trial [Reference]  n ACEI   Comparator F-U  RR (95% CI) p 
                years 
 
STOP-HTN2 [134]   6,614 Enalapril/lisinopril β-blocker 5.0 0.96 (0.72-1.27) NS 
CAPPP [135]  10,985 Captopril  β-blocker-diuretic 6.1 0.79 (0.67-0.94) 0.039 
ALLHAT [136]  33,357 Lisinopril  Chlorthalidone 4.9 0.70 (0.56-0.86) 0.001 
ALLHAT [136]  33,357 Lisinopril  Amlodipine 4.9 0.83 (0.74-0.93) 0.001 
ANBP2 [138]    6,083 Enalapril  (*)  HCTZ  4.1  0.66 (0.54-0.85) 0.001 
ASCOT [137]  19.257 Perindopril    Atenolol  5.5 0.70 (0.63-0.78) 0.001 
PEACE [139]    8,290 Trandolapril (*)  Placebo  4.8  0.83 (0.72-0.96) 0.001 
INVEST [140]  16,176 Trandolapril  HCTZ  2.7  0.85 (0.77-0.95) 0.001 
EUROPA [141]  12,228 Perindopril (*)  Placebo  4.2  0.97 (NA) NS 
HOPE [142,143]    9,297 Ramipril   Placebo  5.0 0.66 (0.51-0.85) 0.001 
 
SOLVD [145] (**)   4,228 Enalapril   Placebo  3.4 0.26 (0.13-0.53) 0.0001 
 
DREAM [146] (***)   5,269 Ramipril   Placebo  3.0 0.91 (0.80-1.03) NS 
 
(*) ACE inhibitor as add-on therapy   
(**) Patients with congestive heart failure 





Table 3 : Randomised clinical trials assessing the effect of angiotensin receptor blockers (ARB) on the incidence 
of diabetes in high-risk patients with hypertension, congestive heart failure and coronary artery disease. 




Trial [Reference] n ARB  Comparator F-U  Relative risk (RR) p 
           years (95% CI) 
 
LIFE [148,149]   9,193 Losartan Atenolol 4.8 0.75 (0.63-0.88)  0.001 
ALPINE [150]      392 Candesartan Atenolol 1.0 0.13 (0.03-0.99)  0.03 
VALUE [151]  15,245 Valsartan Amlodipine 4.2 0.77 (0.69-0.86)  0.0001 
SCOPE [152]   4,937 Candesartan Placebo  3.7 0.81 (0.61-1.02)  0.09 
     
CHARM [153,154] (*)  7,599 Candesartan Placebo  3.2 0.78 (0.64-0.96)  0.02 
 
 




Table 4 : Clinical studies assessing the effect of estrogen replacement therapy on the incidence of new-
onset diabetes in post-menopausal women. 95% CI : 95% confidence interval. 
 
Reference   n  FU Relative  95% CI  p  
      (years) risk 
 
Manson et al 1992 [161] 21,028   12.0 0.80  0.67-0.96  0.005 
Zhang et al 2002 [162]       857    4.0 1.11   0.62-1.97  NS 
Kanaya et al 2003 [164]  2,029    4.1 0.65  0.48-0.89  0.006 
Margolis et al 2004 [165] 15,641   5.6 0.79  0.67-0.93  0.004 
Rossi et al 2004 [163] (**)      673    3.7 0.45  0.29-0.56  0.001 
Bonds et al 2006 [166]  (***) 10,739   7.1 0.88  0.77-1.01  0.072 
 
(*) In this study, the risk of D2TM increased with increasing duration of estrogen use among current 
users 
(**) Only trial performed with transdermal 17-β-estradiol instead of oral conjugated estrogen therapy  
(***) Estrogen alone (without progestin) 
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